You are here

Prevnar 13

Merck snags priority review for Prevnar 13 rival — just one month after Pfizer sent its follow-on to the FDA

Merck snags priority review for Prevnar 13 rival — just one month after Pfizer sent its follow-on to the FDA

Endpoints

pneumococcal disease

priority review

Flag link:

Merck's rival to Pfizer's Prevnar 13 hits goal in phase 3 again

Merck's rival to Pfizer's Prevnar 13 hits goal in phase 3 again

Fierce Biotech

clinical trials

pneumococcal disease

Flag link:

Merck’s pneumonia vaccine posts two more hits

Merck’s pneumonia vaccine posts two more hits

EP Vantage

Flag link:

Homegrown rivals to Pfizer, Merck cash cow vaccines win nods in China

Homegrown rivals to Pfizer, Merck cash cow vaccines win nods in China

Fierce Pharma

Flag link:

Pfizer touts successor to Prevnar 13

Pfizer touts successor to Prevnar 13

Biopharma Dive

pneumococcal disease

Flag link:

U.S. advisory panel stops short of broad recommendations for two common vaccines

U.S. advisory panel stops short of broad recommendations for two common vaccines

Stat

advisory panels

Flag link:

Looking to topple Pfizer's Prevnar 13 dynasty, Merck claims another win for its 'breakthrough' pneumococcal conjugate vaccine

Looking to topple Pfizer's Prevnar 13 dynasty, Merck claims another win for its 'breakthrough' pneumococcal conjugate vaccine

Endpoints

pneumococcal disease

Flag link:

FDA blesses Merck’s PhIII effort to topple a mega-blockbuster — but there’s also a little biotech in this game

FDA blesses Merck’s PhIII effort to topple a mega-blockbuster — but there’s also a little biotech in this game

Endpoints

breakthrough status

Flag link:

Merck pits its pneumococcal shot against Pfizer's mammoth Prevnar in head-to-head ph3

Merck pits its pneumococcal shot against Pfizer's mammoth Prevnar in head-to-head ph3

Fierce Pharma

pneumococcal disease

Flag link:

Don't sweat Prevnar's problems, Pfizer R&D chief says. New vaccines are on their way

Don't sweat Prevnar's problems, Pfizer R&D chief says. New vaccines are on their way

Fierce Pharma

Flag link:

Pfizer's Prevnar 13 set for another price hike in 2018 as U.S. price-per-dose climbs near $180

Pfizer's Prevnar 13 set for another price hike in 2018 as U.S. price-per-dose climbs near $180

Fierce Pharma

Flag link:

Pneumonia vaccine triples protection in animal models

Pneumonia vaccine triples protection in animal models

Fierce Biotech

antibiotic resistance

Flag link:

Prevnar 13 among blockbusters industry watchers peg as tribal licensing candidates

Prevnar 13 among blockbusters industry watchers peg as tribal licensing candidates

Fierce Pharma

Flag link:

Top 25 vaccine products in 2016, based on U.S. sales

Top 25 vaccine products in 2016, based on U.S. sales

Medical Marketing and Media

Flag link:

Pfizer Wins Indian Patent on Prevnar 13 Vaccine

Pfizer Wins Indian Patent on Prevnar 13 Vaccine

RAPS.org

Flag link:

SutroVax raises $64M with plans to challenge Pfizer’s megablockbuster Prevnar 13 for the heavyweight title in vaccines

SutroVax raises $64M with plans to challenge Pfizer’s megablockbuster Prevnar 13 for the heavyweight title in vaccines

Endpoints

pneumococcal disease

Flag link:

Pfizer Has Strong Track Record since 2010

Pfizer Has Strong Track Record since 2010

Market Realist

Flag link:

Pfizer offers cut-price pneumonia shot for humanitarian crises

Pfizer offers cut-price pneumonia shot for humanitarian crises

Yahoo/Reuters

Flag link:

Interesting Trend Developing for Pfizer’s Pneumococcal Franchise

Interesting Trend Developing for Pfizer’s Pneumococcal Franchise

Market Realist

pneumococcal disease

Flag link:

Hillary’s Gift to Big Pharma

Hillary’s Gift to Big Pharma

WSJ Online

Hillary Clinton

2016 Presidential election

Flag link:

Pages